MX2021003265A - Metodos de tratamiento. - Google Patents

Metodos de tratamiento.

Info

Publication number
MX2021003265A
MX2021003265A MX2021003265A MX2021003265A MX2021003265A MX 2021003265 A MX2021003265 A MX 2021003265A MX 2021003265 A MX2021003265 A MX 2021003265A MX 2021003265 A MX2021003265 A MX 2021003265A MX 2021003265 A MX2021003265 A MX 2021003265A
Authority
MX
Mexico
Prior art keywords
treatment methods
methods
cancer
compositions
tumor antigens
Prior art date
Application number
MX2021003265A
Other languages
English (en)
Inventor
Jessica Baker Flechtner
Marie Lossky-Elias
Pamela M Carroll
Hubert Lam
Lisa K Mcneil
Wendy Jane Broom
Original Assignee
Genocea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genocea Biosciences Inc filed Critical Genocea Biosciences Inc
Publication of MX2021003265A publication Critical patent/MX2021003265A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

En la presente se proporcionan métodos y composiciones para identificar antígenos tumorales de linfocitos humanos y para tratar sujetos que tienen cáncer.
MX2021003265A 2018-09-27 2019-09-27 Metodos de tratamiento. MX2021003265A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862737832P 2018-09-27 2018-09-27
US201862757915P 2018-11-09 2018-11-09
PCT/US2019/053672 WO2020069454A1 (en) 2018-09-27 2019-09-27 Treatment methods

Publications (1)

Publication Number Publication Date
MX2021003265A true MX2021003265A (es) 2021-07-15

Family

ID=69952327

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003265A MX2021003265A (es) 2018-09-27 2019-09-27 Metodos de tratamiento.

Country Status (13)

Country Link
US (1) US20230057310A1 (es)
EP (1) EP3856241A4 (es)
JP (1) JP2022502435A (es)
KR (1) KR20210090618A (es)
CN (1) CN113271970A (es)
AU (1) AU2019351274A1 (es)
BR (1) BR112021005221A2 (es)
CA (1) CA3114585A1 (es)
CO (1) CO2021005234A2 (es)
IL (1) IL281839A (es)
MX (1) MX2021003265A (es)
SG (1) SG11202102827YA (es)
WO (1) WO2020069454A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2597623A (en) 2017-08-07 2022-02-02 Univ California Platform for generating safe cell therapeutics
CN114621338B (zh) * 2022-03-11 2022-11-11 中山大学 一种mTOR抑制剂及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0893507A1 (en) * 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
PL203951B1 (pl) * 1999-04-19 2009-11-30 Smithkline Beecham Biolog Kompozycja adiuwantowa, kompozycja szczepionki oraz sposób jej wytwarzania, szczepionka oraz zastosowanie
WO2006039701A1 (en) * 2004-10-01 2006-04-13 University Of South Florida Flagellin-based adjuvants and vaccines
SI2079760T1 (sl) * 2006-12-27 2016-11-30 Emory University Sestavki in metode za zdravljenje okužb
US8628785B2 (en) * 2008-05-16 2014-01-14 Yeastern Biotech Co., Ltd Method for augmenting the immunogenicity of an antigen
TWI565474B (zh) * 2008-05-16 2017-01-11 益生生技開發股份有限公司 一種用於增進一抗原之免疫原性的組合物
AR074844A1 (es) * 2008-12-23 2011-02-16 Intervet Int Bv Composiciones farmaceuticas con saponinas

Also Published As

Publication number Publication date
AU2019351274A1 (en) 2021-05-27
EP3856241A4 (en) 2022-10-05
CO2021005234A2 (es) 2021-07-19
CA3114585A1 (en) 2020-04-02
SG11202102827YA (en) 2021-04-29
BR112021005221A2 (pt) 2021-06-15
EP3856241A1 (en) 2021-08-04
IL281839A (en) 2021-05-31
WO2020069454A1 (en) 2020-04-02
US20230057310A1 (en) 2023-02-23
KR20210090618A (ko) 2021-07-20
JP2022502435A (ja) 2022-01-11
CN113271970A (zh) 2021-08-17

Similar Documents

Publication Publication Date Title
MX2019011148A (es) Metodos de tratamiento.
PH12020551923A1 (en) Methods and compositions for treating cancer
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
NZ725487A (en) Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
MX2021003262A (es) Metodos de tratamiento.
MX2018016183A (es) Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos.
MX2019006331A (es) Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos.
MX2022002244A (es) Metodo para identificar respondedores a degradantes de smarca2/4.
WO2017040666A3 (en) Combination therapy for treatment of disease
MX2020008122A (es) Anticuerpos anti-pd-1.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2019003722A (es) Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.
MX2020006297A (es) Variantes de cd19.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MX2022001841A (es) Anticuerpos contra ilt2 y uso de los mismos.
MX2018009499A (es) Anticuerpos monoclonales especificos de egfl6 y metodos de su uso.
MX2021003265A (es) Metodos de tratamiento.
MX2022014180A (es) Metodos, terapias y usos para tratar cancer.
JOP20210144A1 (ar) أجسام مضادة للبيريوستين واستخداماتها